EN
Home/news
Phrontline Biopharma Raises Nearly $40 Million in Series A Financing to Advance Next-Generation Bispecific and Dual-Payload ADCs
2026-11-16

Round co-led by Oriza Seed Venture Capital and Decheng Capital brings total raised over the past twelve months to approximately $100 million

 

HANGZHOU and SHANGHAI, China, November 13, 2026 — Phrontline Biopharma, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADCs), today announced the close of a Series A financing of nearly $40 million. The round was co-led by Oriza Seed Venture Capital and Decheng Capital, with participation from Lapam Capital, Jifeng Ventures, Medfine Health Fund, Songqing Capital and C&D Emerging Investment.

The financing follows a $60 million Pre-A+ round completed in November 2025, bringing total capital raised over the past twelve months to approximately $100 million.

Proceeds will be used to advance the company’s clinical programs, file INDs for differentiated follow-on candidates, build new payload platforms, and expand international partnerships.

A platform built to widen the therapeutic window of ADC

Conventional ADCs have converged on a narrow set of targets and payload mechanisms. Phrontline takes a different approach, combining bispecific targeting with dual-payload delivery in a single, chemically defined molecule — engaging two tumor antigens to improve tumor selectivity and payload delivery, while delivering two payloads with complementary mechanisms to address resistance to any single cytotoxic class.

The company has built a fully integrated discovery platform spanning antibody discovery and engineering, site-specific conjugation, linker-payload chemistry and functional evaluation, resting on wholly owned intellectual property. Its payload portfolio spans topoisomerase I inhibitors, microtubule inhibitors, DNA alkylators, ATR inhibitors, NMT inhibitors and pan-RAS inhibitors, providing a basis for rational payload pairing.

Clinical progress

TJ101, a bispecific ADC targeting EGFR × B7-H3, is one of the few ADCs of its class in clinical development worldwide. Phase 1a results presented at ESMO 2026 showed a favorable safety and tolerability profile, with encouraging antitumor activity observed across non-small cell lung cancer without actionable genomic alterations, small cell lung cancer, prostate cancer and urothelial carcinoma.

TJ102, a first-in-class bispecific dual-payload ADC targeting FRα × CDH6, is the first ADC of its class worldwide to enter clinical development. Preclinical data presented at AACR 2025 demonstrated clear synergy between the two payloads.

Phrontline has completed out-licensing transactions in both the bispecific ADC and dual-payload ADC segments — partnerships that validate the global value of its platform and pipeline, and establish a path for international development and commercialization.

Management and investor commentary

“ADC development is moving from fast-following toward mechanistic innovation,” said Dr. Tony Chen, Founder and Chief Executive Officer of Phrontline Biopharma. “We have focused on a single question: how to genuinely widen the therapeutic window through innovation in target pairing and payload mechanism. The first clinical data for TJ101, presented at ESMO this year, validated our drug design philosophy, and TJ102 has now entered the clinic. We are grateful for the long-term support of our new and existing investors as we move this next generation of ADCs from concept to clinical benefit.”

“The next-generation ADC field is at a critical inflection point,” said Dr. Xiaojie Zang, Investment Director at Oriza Seed Venture Capital. “What drew us to Phrontline was the differentiated path the team set from the outset — avoiding me-too crowding and committing to next-generation technology. Execution has been strong, the pipeline is advancing efficiently, and multiple business development partnerships have validated the technology from the industry side.”

Decheng Capital, an investor since the Pre-A round, added: “We have watched Phrontline evolve from an early-stage company into a next-generation ADC platform company with leading clinical data. Its product design philosophy, platform innovation and execution have all been validated. We look forward to its continued delivery of innovative medicines for patients worldwide.”

About Phrontline Biopharma

Founded in early 2022 by a team of experienced scientists with backgrounds in global drug development, Phrontline Biopharma is headquartered in Hangzhou with an R&D center in Shanghai. The company develops next-generation antibody-drug conjugates built on a globally competitive bispecific and dual-payload ADC platform, with multiple programs in early clinical development and IND-enabling studies.